Flibanserin for hypoactive sexual desire disorder in premenopausal women
Flibanserin is a mixed 5-HT1A agonist and 5-HT2A antagonist approved for treating premenopausal women with hypoactive sexual desire disorder (HSDD). It is the first FDA-approved medication for this condition, showing efficacy by increasing the number of satisfying sexual events. However, flibanserin has been associated with side effects, including hypotension and
June 26, 2025
No Comments